Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Gains Conditional NYS Approval for Pediatric Disorders Array Test

NEW YORK (GenomeWeb) – CombiMatrix announced today that it has received conditional approval from the New York State Department of Health to market its CombiSNP chromosomal microarray analysis test for pediatric development disorders.

By gaining conditional approval, CombiMatrix will be able to market the test in New York while the assay is under Clinical Laboratory Reference System review. Upon completion of the review, either the test will receive full approval or additional information will be required in order to achieve final approval, the company said.

"We have focused our market development activities on our miscarriage analysis test over the past year and now we plan to expand our activity to address pediatric disorders," CombiMatrix CEO Mark McDonough said in a statement.

The New York State Department of Health granted CombiMatrix conditional approval last year to market its CombiSNP CMA test for miscarriage analysis.

CombiMatrix's tests are offered through its CLIA-compliant lab in Irvine, Calif.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.